




## ABSTRACT

There is provided a T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, of formula (1)



wherein R<sup>1</sup> and R<sup>2</sup> are independently of each other C<sub>1-6</sub> alkyl group or R<sup>1</sup> and R<sup>2</sup> together form -CR<sup>5</sup>R<sup>6</sup>-CR<sup>7</sup>R<sup>8</sup>-, -CR<sup>5</sup>R<sup>6</sup>-CR<sup>7</sup>R<sup>8</sup>-CR<sup>9</sup>R<sup>10</sup>- or -CR<sup>5</sup>R<sup>6</sup>-CR<sup>7</sup>R<sup>8</sup>-CR<sup>9</sup>R<sup>10</sup>-CR<sup>11</sup>R<sup>12</sup>-, etc., X<sup>1</sup> and X<sup>2</sup> are independently of each other O or NR<sup>13</sup>, Ar is optionally substituted phenyl group, etc., R<sup>a</sup> and R<sup>b</sup> are independently of each other C<sub>1-6</sub> alkyl group, -L<sup>2</sup>-NR<sup>16</sup>R<sup>17</sup>, CH<sub>2</sub>O-L<sup>2</sup>-NR<sup>16</sup>R<sup>17</sup>, CN, -L<sup>2</sup>-N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>NR<sup>16</sup> or NR<sup>16</sup>R<sup>17</sup>, etc., Y is C<sub>1-20</sub> alkyl group, -L<sup>3</sup>-NR<sup>18</sup>R<sup>19</sup>



and \* is absolute configuration of R.